Caricamento...
Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients
BACKGROUND: Multiple sclerosis (MS) registry data, primarily from Europe, suggest that treatment with natalizumab delays time to relapse compared with platform therapy (interferon beta/glatiramer acetate). OBJECTIVE: This study uses US administrative claims data and propensity score matching (PSM) t...
Salvato in:
| Pubblicato in: | CNS Drugs |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer International Publishing
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4513191/ https://ncbi.nlm.nih.gov/pubmed/26113055 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40263-015-0251-1 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|